Vaccinex isn't chasing the latest mRNA hype—they're playing a far more dangerous game. With $65.9M in funding and a single, high-stakes clinical program targeting both cancer and neurodegenerative disease, this is biotech with a singular, almost obsessive focus. The website screams 'science-first,' but the numbers tell a story of a company at a critical inflection point.

"They aren't building a platform—they're building a proof of concept. One molecule, two massive indications, and a valuation that hinges entirely on clinical data."

The leadership team is industry-veteran heavy, with CEO Maurice Zauderer and COO Elizabeth Evans steering the ship through the brutal waters of Phase 2 trials. Their tech stack is standard—WordPress, jQuery, Google Analytics—showing they invest in science, not flashy web dev. The real investment is in the lab, where they're trying to validate a hypothesis that could redefine treatment for Alzheimer's and metastatic cancer.

• Revenue of $12.6M suggests early commercial or partnership income, not just cash burn.
• Traffic is dominated by financial queries, not clinical or scientific discovery.
• The site is static and informational, signaling a company in 'data-waiting' mode rather than active recruitment or marketing.